Sublingual immunotherapy (SLIT) is significantly less concerned by systemic reactions than subcutaneous immunotherapy. Allergoids were introduced to reduce systemic reaction to subcutaneous immunotherapy, but may also be used for SLIT. This pharmacovigilance study evaluated the post-marketing reports collected in a safety database, including the number and the type (serious or not serious) of adverse drug reactions (ADRs) in Italy by SLIT with the carbamylated monomeric allergoid (CMA). More than 15,000,000 CMA tablets were administered, with 25 spontaneous reports of ADRs, only two being serious. The rate of ADRs to CMA we found in this pharmacovigilance survey, corresponding to 0.0004% of all administered doses, is far lower than the rates commonly reported for allergen SLIT products.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2019-0095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and tolerability of house dust mites subcutaneous immunotherapy with monomeric allergoid: an Italian multicenter study.
Eur Ann Allergy Clin Immunol
October 2024
Lofarma S.p.A., Scientific Medical Department, Milan, Italy.
Subcutaneous immunotherapy is an effective treatment of respiratory allergy and allergoids offer a treatment option characterized by reduced IgE-binding properties to improve the safety profile. Purpose of this study was to investigate the efficacy and the safety of an injective monomeric allergoid in patients with moderate to severe persistent allergic rhinitis due to house dust mites. in a perspective, controlled, observational study a suspension of 0.
View Article and Find Full Text PDFSafety of subcutaneous and sublingual immunotherapy with allergoids in children: a real-life pharmacovigilance study.
Immunotherapy
January 2024
Outpatients Depatrment, Allergy Center, Casa di Cura Villa Montallegro, 16145, Via Montezovetto, Genoa, Italy.
Allergen-specific immunotherapy uses a sublingual (sublingual immunotherapy [SLIT]) or subcutaneous (subcutaneous immunotherapy [SCIT]) route. This pharmacovigilance study aimed to determine the number and type of adverse drug reactions (ADRs) for SLIT and SCIT using carbamylated monomeric allergoids (CMAs) in children. This pharmacovigilance study analyzed real-world post-marketing reports collected from a safety database of Lais sublingual tablets and injective Lais-in, containing CMAs for over 10 years.
View Article and Find Full Text PDFReal-Life Effectiveness of Subcutaneous Immune Therapy with Carbamylated Monomeric Allergoids on Mite, Grass, and Pellitory Respiratory Allergy: A Retrospective Study.
J Clin Med
December 2022
Centre of Advanced Studies and Technology (CAST), G. d'Annunzio University, 66100 Chieti, Italy.
Background: real-life studies are encouraged to evaluate the effectiveness and safety of allergen immunotherapy (AIT). In this context, a retrospective cohort study was conducted to assess the effectiveness and safety of carbamylated monomeric allergoid subcutaneous immunotherapy (MA-SCIT), along with patient satisfaction. Methods: a total of 291 patients with rhinoconjunctivitis with or without asthma with inhalant (house dust mite, grass, and pellitory) allergies were enrolled in this study.
View Article and Find Full Text PDFSafety of subcutaneous immunotherapy with carbamylated allergoids based on data from a pharmacovigilance database.
Immunotherapy
October 2022
Scientific & Medical Department, Lofarma S.p.A., Milan, Italy.
Allergen immunotherapy aims to induce tolerance, which persists after its discontinuation, to targeted allergens. However, concern exists regarding the use of subcutaneous immunotherapy with whole extracts due to frequently reported events of anaphylactic reactions. In this pharmacovigilance study, the authors assessed the safety of subcutaneous immunotherapy with the monomeric allergoid Lais-in using a database of adverse reactions documented in real-world postmarketing reports from 2010 to 2020.
View Article and Find Full Text PDFCross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load.
Arthritis Res Ther
September 2021
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Background: Anti-modified protein antibodies (AMPA) targeting citrullinated, acetylated and/or carbamylated self-antigens are hallmarks of rheumatoid arthritis (RA). Although AMPA-IgG cross-reactivity to multiple post-translational modifications (PTMs) is evident, it is unknown whether the first responding B cells, expressing IgM, display similar characteristics or if cross-reactivity is crucially dependent on somatic hypermutation (SHM). We now studied the reactivity of (germline) AMPA-IgM to further understand the breach of B cell tolerance and to identify if cross-reactivity depends on extensive SHM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!